Response and tolerance to oral vasodilator up‐titration after intravenous vasodilator therapy in advanced decompensated heart failure

The aim of this study was to assess the haemodynamic response and tolerance to aggressive oral hydralazine/isosorbide dinitrate (HYD/ISDN) up‐titration after intravenous vasodilator therapy in advanced decompensated heart failure (ADHF).

[1]  S. Janssens,et al.  Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension , 2015, European journal of heart failure.

[2]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[3]  C. Yancy,et al.  Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. , 2013, JACC. Heart failure.

[4]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[5]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[6]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[7]  K. Conrad,et al.  Ernest H. Starling Distinguished Lectureship of the Water and Electrolyte Maternal Vasodilation in Pregnancy: the Emerging Role of Relaxin , 2022 .

[8]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[9]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[10]  R. Porcher,et al.  Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods , 2011, Intensive Care Medicine.

[11]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[12]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[13]  R. Starling,et al.  Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. , 2009, The American journal of cardiology.

[14]  R. Starling,et al.  Sodium nitroprusside for advanced low-output heart failure. , 2008, Journal of the American College of Cardiology.

[15]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[16]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[17]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[18]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[19]  E Erdmann,et al.  The failing human heart is unable to use the Frank-Starling mechanism. , 1994, Circulation research.

[20]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[21]  P. Binkley,et al.  Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. , 1991, The American journal of cardiology.

[22]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[23]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[24]  J. Cohn,et al.  Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. , 1982, American heart journal.

[25]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[26]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[27]  S. Werns.  Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[28]  J. Cohn,et al.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. , 1978, Chest.

[29]  C. Lafarge,et al.  The estimation of oxygen consumption. , 1970, Cardiovascular research.